Natco Pharma (BOM:524816) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma Debt-to-Equity?

Natco Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹3,659 Mil. Natco Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹53 Mil. Natco Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹58,531 Mil. Natco Pharma's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Natco Pharma's Debt-to-Equity or its related term are showing as below:

BOM:524816' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.09 Max: 0.38
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Natco Pharma was 0.38. The lowest was 0.04. And the median was 0.09.

BOM:524816's Debt-to-Equity is ranked better than
78.74% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:524816: 0.06

Natco Pharma Debt-to-Equity Historical Data

The historical data trend for Natco Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma Debt-to-Equity Chart

Natco Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.07

0.10

0.04

0.06

Natco Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	N/A	0.05	N/A	0.06

Competitive Comparison of Natco Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natco Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Debt-to-Equity falls into.

Natco Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Natco Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3659	+	53)	/	58531
	=	0.06

Natco Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3659	+	53)	/	58531
	=	0.06

Natco Pharma (BOM:524816) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Natco Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Natco Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Natco Pharma (BOM:524816) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » Debt-to-Equity

Traded in Other Exchanges

NATCOPHARM:India

Address

Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034

Website

https://www.natcopharma.co.in

Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines